ACE and heart failure: However, dysglycemia is associated with a higher risk of adverse cardiovascular outcomes in type 2 diabetic (T2DM) patients than in nondiabetic patients with heart failure and reduced ejection fraction (HFrEF), independently of the medical therapy, including angiotensin-converting enzyme inhibitor (ACE-I) or angiotensin receptor blocker (ARB) [5, 6].